Biotech stock Alkermes plunges 20% after FDA refuses to review its depression treatment

Posted in IT

  Richard Pops, chairman and chief executive officer of Alkermes Shares of biotech company¬†Alkermes¬†dropped 20 percent Monday after announcing the U.S. Food and Drug Administration refused to review the firm’s drug for treating depression. The stock tumbled 20 percent to around $46.25 a share in morning trading. As of Thursday’s close, Alkermes was up 5.9….

Biotech stock Alkermes plunges 20% after FDA refuses to review its depression treatment